On 12 Nov 2026 Cooper Companies (The) closed at $62.19, -24.1% this year; market cap $12.03bn, P/E 21.1.
Health Care · Health Care Supplies · NASDAQ · United States
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
| Market cap | $12.03bn |
| P/E (trailing) | 21.1 |
| EPS (TTM) | $2.95 |
| Beta | 0.82 |
| Dividend | $0.00 |
| Dividend yield | 0.00% |
| Ex-dividend date | 26 Jul 2023 |
| Latest report | 9 Sep 2026 |
| Next earnings | 3 Dec 2026 |
| YTD | -24.1% |
| 1Y | -14.2% |
| 3Y | -9.1% |
| 5Y | -9.8% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $4.09bn | $374.90m | $433.70m |
| 2024 | $3.90bn | $392.30m | $288.10m |
| 2023 | $3.59bn | $294.20m | $215.00m |
| 2022 | $3.31bn | $385.80m | $450.40m |
| 2021 | $2.92bn | $2.94bn | $524.20m |
Base value $51.28 (-17.5% vs price); 0 of 1 methods above the price. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.